What's Happening?
Selagine Plasma, Inc. has announced the development of a new investigational pooled plasma eye drop program aimed at treating moderate-to-severe dry eye disease. This initiative is supported by intellectual property rights from Selagine, Inc. and the University
of Illinois Chicago. The program seeks to transition from individualized serum tears to a standardized biologic manufacturing model. The new platform involves screened donors, plasmapheresis collection, and closed-system manufacturing, with a focus on reducing inflammatory mediators while retaining beneficial plasma components. The goal is to create an off-the-shelf product that can be distributed through conventional pharmacy channels, pending FDA approval.
Why It's Important?
This development represents a significant advancement in the treatment of dry eye disease, which affects millions of Americans, particularly older adults and women. Current treatments, such as serum tears, are often limited by individualized preparation processes that are not FDA-approved. By moving towards a standardized, scalable model, Selagine Plasma aims to improve patient access to effective treatments and potentially reduce the burden of ocular surface inflammation associated with dry eye disease. This could lead to better patient outcomes and more efficient healthcare delivery.
What's Next?
Selagine Plasma plans to pursue an appropriate FDA development pathway to gain approval for their pooled plasma eye drop product. If successful, this could pave the way for broader commercialization and distribution, making the treatment more accessible to patients. The company will continue to refine its manufacturing processes and work towards meeting regulatory requirements. The potential for insurance coverage and reimbursement will also be explored, which could further enhance patient access to this innovative treatment.
